lung cancer

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

AstraZeneca to unveil key data for cancer drugs at ASCO

AstraZeneca plans to unveil data at this year’s American Society of Clinical Oncology (ASCO) conference that could expand the number of patients who could be treated with two of its most im

News

NICE backs drugs for lymphoma and lung cancer from Roche and...

NICE has recommended NHS funding for a duo of cancer drugs, giving final guidance on new options for certain patients with follicular lymphoma and lung cancer.

News

Sanofi and Regeneron eye challenge to Merck & Co in first li...

Sanofi and Regeneron could mount a challenge to Merck & Co’s Keytruda in untreated advanced lung cancer with their cancer immunotherapy latecomer Libtayo following new phase 3 results.

News

Tagrisso trial halted early after ‘overwhelming’ efficacy

A phase III trial for AstraZeneca’s lung cancer drug Tagrisso (osimertinib) will be unblinded early after strong results.

News

FDA approves AZ Imfinzi in new lung cancer use

AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic ki

News

AZ's immunotherapy combo fails in phase 3 lung cancer trial

AstraZeneca’s Imfinzi plus standard chemo improves overall survival in untreated extensive-stage small cell lung cancer – but a combination therapy involving another immunotherapy does not,

AstraZeneca to unveil key data for cancer drugs at ASCO

NICE backs drugs for lymphoma and lung cancer from Roche and...

Sanofi and Regeneron eye challenge to Merck & Co in first li...

Tagrisso trial halted early after ‘overwhelming’ efficacy

FDA approves AZ Imfinzi in new lung cancer use

AZ's immunotherapy combo fails in phase 3 lung cancer trial

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

lung cancer

Editor's Picks